{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-068845","form_type":"8-K/A","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.590808+00:00","generated_at":"2026-05-24T01:40:18.239817+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Whitehawk closes sale of Aadi Subsidiary for $102.4M; pro forma cash $131M; FY2024 pro forma loss $25.2M","bullets":["Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.","Pro forma balance sheet as of Dec 31, 2024 shows cash & equivalents of $131.1M.","Estimated gain on sale of $93.2M recorded; pro forma FY2024 net loss improves to $25.2M from historical $63.7M.","Aadi revenue ($26.0M) and operating expenses ($64.3M) removed from pro forma statement.","Stockholder approval obtained February 28, 2025; company retains no FYARRO program revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-068845","json":"https://secwatch.observer/filing/0001193125-25-068845.json","markdown":"https://secwatch.observer/filing/0001193125-25-068845.md","text":"https://secwatch.observer/filing/0001193125-25-068845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/0001193125-25-068845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/d924652d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:40:18.239817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}